Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

por Bota, Daniela A, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Elias, Ileana, Reich, Steven D, Levin, Nancy, Trikha, Mohit, Desjardins, Annick
Publicado 2021

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

por Saura-Esteller, José, de Jong, Milon, King, Lisa A., Ensing, Erik, Winograd, Benjamin, de Gruijl, Tanja D., Parren, Paul W. H. I., van der Vliet, Hans J.
Publicado 2022

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

por Lameris, Roeland, Ruben, Jurjen M., Iglesias-Guimarais, Victoria, de Jong, Milon, Veth, Myrthe, van de Bovenkamp, Fleur S., de Weerdt, Iris, Kater, Arnon P., Zweegman, Sonja, Horbach, Sjeng, Riedl, Thilo, Winograd, Benjamin, Roovers, Rob C., Adang, Anton E.P., de Gruijl, Tanja D., Parren, Paul W.H.I., van der Vliet, Hans J.
Publicado 2023